With continuous efforts to find new cancer treatments, comes to life a new ultrasound technology developed by a US based company called HistoSonics the device works by destroying cancerous liver cells in a non-invasive way without the need for surgery, scalpels or radiation, with little to no damage to surrounding organs.

The National Health Service (NHS) patients will be the first to experience this groundbreaking technology, making cancer treatment a more seamless experience with reduced treatment time as it takes less than 30 minutes for one treatment session with limited to no pain, making patients carry on with their day regularly. Moreover, it will help in reducing hospital stays drastically as it has shown less complications compared to standard cancer treatment approaches.

To cut delays and boost innovation, Health Secretary Wes Streeting approved early access to the device under an unmet clinical need authorisation. Through the UK’s government-funded Innovative Devices Access Pathway, NHS patients can now benefit from this advanced technology years ahead of schedule.

Backed by a generous donation from the Li Ka Shing Foundation to the University of Cambridge, this advancement supports the UK's goal of becoming a global tech leader in healthcare. Experts, including NHS leaders, regulators, and patient advocates, have praised histotripsy for its potential to transform cancer care, particularly for patients not eligible for surgery.

This milestone marks not just a leap in medical technology—but a shift toward smarter, faster, and more patient-centered care across the NHS.

Learn more: NHS red tape blitz delivers game-changing new cancer treatment - GOV.UK